PMID- 34889371
OWN - NLM
STAT- MEDLINE
DCOM- 20211221
LR  - 20220327
IS  - 1520-4383 (Electronic)
IS  - 1520-4391 (Print)
IS  - 1520-4383 (Linking)
VI  - 2021
IP  - 1
DP  - 2021 Dec 10
TI  - Evidence-Based Minireview: In young children with severe sickle cell disease, do 
      the benefits of HLA-identical sibling donor HCT outweigh the risks?
PG  - 190-195
LID - 10.1182/hematology.2021000322 [doi]
AB  - In case 1, a 14-month-old male child with sickle cell disease (SCD) was referred 
      for evaluation for an allogeneic hematopoietic stem cell transplant (HCT). The 
      patient had a history of dactylitis 3 times in his first year of life and febrile 
      episodes twice at the consult. His 4-year-old sister was found to be human 
      leukocyte antigen (HLA) identical. The patient was started on hydroxyurea (HU) at 
      2.5 years of age. His parents again sought consultation when he was 5 years old 
      because of concerns about his medical condition. At the time, the patient had 
      experienced 2 vaso-occlusive pain episodes (VOEs) requiring hospitalization 
      during the previous 2 years. He had also experienced intermittent pain crises 
      requiring rest at home for 2 to 3 days. The child has not attended school in 
      person due to the COVID-19 pandemic. The family is considering HCT but is 
      ambivalent about it because of potential toxicity. In case 2, an 8-year-old 
      female child is 3 years out from HCT for SCD from her HLA-identical sibling. 
      Before HCT, despite receiving HU, she had experienced >5 VOEs requiring 
      hospitalization and 2 episodes of acute chest syndromes in the previous 3 years. 
      She had also been missing almost 50 days of school days each year. After HCT, she 
      is now attending school regularly and participating in all normal age-appropriate 
      activities. The parents believe that HCT has been transformative in their child's 
      life.
CI  - Copyright (c) 2021 by The American Society of Hematology.
FAU - Shah, Niketa
AU  - Shah N
AD  - Section of Pediatric Hematology/Oncology/BMT, Yale School of Medicine, New Haven, 
      CT.
FAU - Krishnamurti, Lakshmanan
AU  - Krishnamurti L
AD  - Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory 
      University, Atlanta, GA.
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Hematology Am Soc Hematol Educ Program
JT  - Hematology. American Society of Hematology. Education Program
JID - 100890099
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Age Factors
MH  - Anemia, Sickle Cell/epidemiology/*therapy
MH  - Child
MH  - Child, Preschool
MH  - Evidence-Based Medicine
MH  - Female
MH  - HLA Antigens/analysis
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects/methods
MH  - Humans
MH  - Infant
MH  - Male
MH  - Quality of Life
MH  - Risk Factors
MH  - Siblings
MH  - Tissue Donors
PMC - PMC8791135
COIS- Niketa Shah: no competing financial interests to declare. Lakshmanan 
      Krishnamurti: no competing financial interests to declare.
EDAT- 2021/12/11 06:00
MHDA- 2021/12/22 06:00
PMCR- 2021/12/10
CRDT- 2021/12/10 08:45
PHST- 2021/12/10 08:45 [entrez]
PHST- 2021/12/11 06:00 [pubmed]
PHST- 2021/12/22 06:00 [medline]
PHST- 2021/12/10 00:00 [pmc-release]
AID - 482945 [pii]
AID - 2021000322 [pii]
AID - 10.1182/hematology.2021000322 [doi]
PST - ppublish
SO  - Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):190-195. doi: 
      10.1182/hematology.2021000322.